• The partnership combines Secarna’s OligoCreator^® technology with Vect-Horus’ VECTrans^® platform to enable systemic delivery of oligonucleotide therapies across the blood-brain barrier
• This collaboration marks a strategic step for both companies in expanding their presence in targeted delivery and CNS indications, uniting complementary expertise in RNA therapeutics and advanced delivery technologies
• This strategic agreement unlocks new potential treatments for neurodegenerative and other CNS disorders and delivering solutions that truly impact patient lives
  
  

 Secarna Pharmaceuticals GmbH & Co. KG, a company redefining the discovery and development of best-in-class oligonucleotide therapeutics, and Vect-Horus, an expert in the design and development of molecular vectors to facilitate targeted delivery of therapeutic molecules and imaging agents, today announced that the companies have entered into a strategic research collaboration to develop RNA-targeted therapeutics capable of crossing the blood-brain barrier (BBB) to address diseases of the central nervous system (CNS).

The partnership will combine Vect-Horus’ expertise and delivery technology platform, VECTrans^®, a versatile delivery system focused on shuttling therapeutic or imaging payloads across biological barriers, with Secarna’s proprietary OligoCreator^® oligonucleotide discovery platform. The combination of these two technologies will expand Secarna’s targeted delivery portfolio, offering a novel approach that could potentially transform the treatment of neurodegenerative diseases.

"This partnership brings together two complementary platforms to address one of the most challenging aspects of CNS drug development - effective, targeted, and systemic delivery across the blood-brain barrier," said Konstantin Petropoulos, PhD, Chief Executive Officer of Secarna Pharmaceuticals. "Our collaboration with Vect-Horus, whose VECTrans^® technology has earned major recognition in the world, marks a significant step in our strategic expansion into targeted delivery in the context of CNS diseases, unlocking new possibilities for treating neurodegenerative and other CNS disorders and delivering solutions that truly impact patient lives."

“We are pleased to collaborate with Secarna Pharmaceuticals” said Alexandre Tokay, co-founder and CEO of Vect-Horus. “By combining our VECTrans^® delivery platform with Secarna’s OligoCreator^® technology, we aim to advance RNA-targeted therapies for CNS disorders. This research collaboration represents a unique opportunity to overcome the long-standing delivery challenges through the blood-brain barrier and bring forward innovative treatment options for patients who today have limited and ineffective treatment options”

With over 20 years of expertise Vect-Horus’ VECTrans^® platform uses engineered peptide and single-domain, heavy chain-only (VHH) antibody vectors to shuttle therapeutic or imaging payloads—ranging from small molecules and oligonucleotides to proteins—across biological barriers like the blood–brain barrier via receptor-mediated transport. This approach enables efficient targeting of specific cells or tissues (e.g., the CNS or tumors) while enhancing pharmacokinetics and minimizing off-target effects. VECTrans^® has been validated in multiple preclinical animal models for a variety of diseases. In addition, the platform has one partnered program in the clinical stage targeting glioblastoma multiforme and pancreatic cancer.

Secarna’s AI-empowered OligoCreator^® platform unites multiple delivery solutions with safety and efficacy assessment tools to rapidly discover and refine highly effective and safe oligonucleotide therapies. This powerful integration enhances Secarna’s ability to address diseases once considered untreatable, reinforcing the platform’s critical role in driving the next generation of medical innovation.